MedWatch, and how problems with medicines get reported to FDA

FDA's adverse event database took in 1,307,794 reports about drugs and therapeutic biologics received in 2025, according to GxRadar's count of openFDA's adverse event data¹. Consumers and other non-health professionals were listed as the original source on 626,040 of them, 48 percent. Many reports of every kind reach FDA secondhand, from drug companies that are required to forward what they hear.

Forms the public sends FDA directly make up a much smaller stream. In a June 2025 paperwork notice, FDA estimated it receives 58,711 voluntary Form 3500 reports a year about drugs and biologics and 18,961 consumer Form 3500B reports at its drug center, according to the Federal Register². Both forms belong to MedWatch, the program FDA started in July 1993.

MedWatch³ is FDA's route for reporting side effects, product quality problems, medication errors and drugs that seem not to work, including after a switch between generic makers. This explainer covers who can report and on which form, how a quality complaint differs from an adverse event, what the law requires of manufacturers, and what FDA does once a report arrives.

How MedWatch began and who it is for

"Since 1993, mandatory adverse event reporting has been supplemented by voluntary reporting by healthcare professionals, patients, and consumers via the MedWatch reporting process," FDA wrote in the 2025 notice². Individual health professionals and consumers are not required to report anything. Hospitals are not required to report drug problems either, the notice says, though device deaths and serious injuries are another matter.

Congress pushed the phone number outward twice. The Best Pharmaceuticals for Children Act required the MedWatch number or web address on outpatient prescriptions, and FDA's rule at 21 CFR 209¹³ spells out the verbatim side effects statement pharmacies distribute: "Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088." The FDA Amendments Act of 2007 added a similar line to printed consumer drug ads. The same number appears in the Highlights section of modern prescription labeling, as GxRadar's guide to what a prescription label contains explains.

Those form descriptions come from FDA's reporting page and the 2025 notice. Vaccine problems go to a separate system, VAERS, and tobacco and dietary supplement reports have their own portal.

What counts as a reportable problem

MedWatch takes "serious reactions, product quality problems, therapeutic inequivalence/failure, and product use errors," according to FDA's reporting page⁴. FDA treats an event as serious when the outcome is death, a life-threatening situation, a hospital admission or longer stay, disability or permanent damage, a congenital anomaly or birth defect, or another important medical event, according to its serious adverse event page⁵.

Form 3500B casts a wider net. It lists being hurt or having a bad side effect, using a product incorrectly, noticing a quality problem, and having "problems with how a drug worked after switching from one maker to another maker," according to the form's instructions⁷. That last item is the one most specific to generics.

Product problems are their own category. FDA wants reports "when there is a concern about the quality, authenticity, performance, or safety of any medication or device," its product problems page⁶ says, adding that a pharmacist is often the first to notice. Its examples include a pharmacist who heard glass rattling inside a small bottle of diphenhydramine syrup; the investigation traced a glass-bottle production problem and ended in a nationwide recall.

For generics, details matter. FDA's form instructions⁸ say that when reporting a quality problem or therapeutic failure for a generic, "it is essential" to give the manufacturer's name, strength, NDC number and lot number. The NDC "is usually not found on dispensed pharmacy prescriptions," the instructions note, and they suggest asking the dispensing pharmacy. GxRadar explains those codes in its piece on package barcodes and its NDC explainer.

What manufacturers must send

A company that hears about a problem has deadlines. Under 21 CFR 314.80¹⁰, an application holder must report each adverse drug experience that is both serious and unexpected "as soon as possible but no later than 15 calendar days" after first learning of it. Separately, 21 CFR 314.81¹¹ requires a field alert report within three working days for any incident that causes a drug or its labeling to be mistaken for another article, and for contamination, significant deterioration or a batch that fails its specifications. Generic application holders carry the same duties under 21 CFR 314.98¹².

Those requirements explain why the openFDA data are so large. "If a manufacturer receives an adverse event report, it is normally required to send the report to FDA," openFDA's documentation¹ says.

Counts are reports in openFDA by receipt year and the primary source's listed qualification, through data updated Oct. 28, 2026; lawyers and reports with no qualification are not shown, and follow-ups to a case are filed as separate reports.

What FDA does with a report

FDA staff enter each report into a database, and a safety evaluator, "often a pharmacist, doctor, or nurse," reviews it and searches for similar ones, according to FDA's consumer guide⁹. Possible actions range from safety alerts and labeling changes to inspections, new Medication Guides, design or manufacturing changes, and recall requests. "As few as one or two complaints can make a difference," the same guide says.

The database has a new name. FDA's Adverse Event Monitoring System page¹⁴, last updated in March 2026, carries the note "Formerly FDA Adverse Event Reporting System (FAERS)" and says AEMS will consolidate reporting systems across all FDA-regulated products and also handle consumer complaints and whistleblower submissions. Its public dashboard page¹⁵ repeats the limits that applied to FAERS: duplicate and incomplete reports exist, and "existence of a report does not establish causation." FDA also posts quarterly lists of potential signals, and a drug's appearance there "does not mean that FDA has concluded" it has the risk, according to the signals page¹⁶. GxRadar's explainer on the FAERS database covers how to read the data, and quality-driven recalls are tracked on the recalls page.

How a consumer files a report

FDA offers an online reporting form and a downloadable Form 3500B, and callers to its general line, 1-888-INFO-FDA, can press 2 for MedWatch, according to its reporting page⁴. The form itself lists a toll-free number, 1-800-332-1088, which spells 1-800-FDA-1088. Paper forms go by mail to the MedWatch program in Silver Spring, Maryland, or by toll-free fax to 800-332-0178, according to the form⁷, which asks reporters to keep the product, include photos if possible and not send the product to FDA.

FDA's complaint system and MedWatch "are for reporting problems; neither provides medical advice," its consumer guide⁹ says, and it tells anyone who has an adverse event to contact a health care professional first and then report. The reporting page encourages patients to take the form to their doctor, while noting that a provider "is NOT required to report." On identity, FDA's instructions⁸ say the agency will not disclose a reporter's identity in response to a public records request, though it may share it with the manufacturer for follow-up unless the reporter asks it not to.

Form 3500B carries an OMB expiration date of Sept. 30, 2027. GxRadar's guide to checking whether a medicine was recalled covers the other direction, from FDA back to the public.